drugset / Trial / NCT00608374

Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

NCT00608374

Phase 3 Completed 400 enrolled Taunton and Somerset Hospital
RandomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as chlorambucil and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known whether chlorambucil is more effective than fludarabine in treating Waldenström macroglobulinemia, splenic lymphoma, or lymphoplasmacytic lymphoma. PURPOSE: This randomized phase III trial is studying chlorambucil to see how well it works compared with fludarabine as first-line therapy in treating patients with previously untreated Waldenström macroglobulinemia, splenic lymphoma, or lymphoplasmacytic lymphoma.

Timeline

Start
2006-06
Primary completion
2009-12
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorambucil Other / unclassified Oral
Subject Fludarabine Small molecule Oral

Indications